AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. FDX
3. META
4. ABBV
5. MU
6. SPY
7. ACN
8. BLZE
9. IBM
10. NKE

Go back to AbbVie (ABBV) Reports ABBV-951Showed Improvement in Controlling Motor Fluctuations Compared to Oral Levodopa/Carbidopa Medication in Pivotal Phase 3 Trial
AbbVie (NYSE: ABBV) Delayed: 234.76 --0 (-0%)
Previous Close $234.76    52 Week High $68.12 
Open $234.76    52 Week Low $50.71 
Day High $234.76    P/E 50.92 
Day Low $234.76    EPS $4.61 
Volume 727